Breaking News, Financial News

J&J FY Revenues up 14%

Janssen COVID-19 Vaccine contributes $1.6 billion in the quarter and $2.4 billion for the year.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson 4Q Revenues: $24.8 billion (+10%) 4Q Earnings: $4.7 billion (+173%) FY Revenues: $93.8 billion (+14%)   FY Earnings: $20.9 billion (+42%) Comments: Pharmaceutical sales were $52.1 billion, up 14% for the year, driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), for the treatment of a number of immune- mediated inflammatory diseases, TREMFYA (guselkumab), for the treatment of moderate to severe plaque psoriasis, and active pso...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters